Patents by Inventor Purav Vagadia

Purav Vagadia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF TISSUE TRANSGLUTAMINASE 2 (TG2) AND USES THEREOF
    Publication number: 20210276960
    Abstract: Disclosed are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. The disclosed compounds inhibit the activity of tissue transglutaminase 2 (TG2). As such, the disclosed compounds and pharmaceutical compositions may be utilized in methods for treating a subject having or at risk for developing a disease or disorder that is associated with TG2 activity which may be cell proliferative diseases and disorders such as cancer.
    Type: Application
    Filed: March 3, 2021
    Publication date: September 9, 2021
    Inventors: Gary E. Schiltz, Daniela E. Matei, Purav Vagadia
  • Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
    Patent number: 10851082
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: December 1, 2020
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Javier Izquierdo-Ferrer, Purav Vagadia, Matthew R. Clutter, Rama K. Mishra, Leonidas C. Platanias
  • SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2)
    Publication number: 20180244654
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Javier Izquierdo-Ferrer, Purav Vagadia, Matthew R. Clutter, Rama K. Mishra, Leonidas C. Platanias